System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Christos Chouaid is an expert in Oncology at Hôpital Intercommunal de Créteil (France). As of October 2026, ScienceLeadR ranks Christos Chouaid in the top 1% of experts worldwide for Thoracic Neoplasms, Lung Neoplasms and Bronchial Neoplasms. Christos Chouaid has authored 885 publications, the most recent in 2026, and is an investigator in 53 clinical trials, 13 of them ongoing. SLR score: 3,513 (community average: 125). How the SLR is computed.

LeadR Profile

Christos Chouaid Hôpital Intercommunal de Créteil France
3 513 ScienceLeadR Reputation 3513

Unlock

Register Login
Network Map

Oncology

Subspecialties: Pulmonology - Public Health - Geriatrics

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 1991 - 2026
Source: PubMed

Hôpital Intercommunal de Créteil

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 885

Citations

Citations: 18 496 1st author: 115 Last author: 222 Unique author: 11

Main journals

Rev Mal Respir 119
Ann Oncol 68
Lung Cancer 66
J Thorac Oncol 62
Value Health 58

Best Journals

Ann Oncol 40
J Clin Oncol 13
Lancet Oncol 8

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Treatment patterns and outcomes in advanced and metastatic lung cancer in France: Results from the Epidemiological Strategy and medical Economics (ESME) database lung cancer in France.
PMID 42660015 — cells, lung, neoplasms, carcinoma, non-small-cell lung, economics, medical, lung neoplasms, therapeutics, economics		Lung Cancer20260
Second-line chemotherapy efficacy is not affected by prior exposure to immunotherapy in extensive-disease small-cell lung cancer: results from the ESME French national real-world cohort.
PMID 42567006 — cells, lung, neoplasms, propensity score, drug therapy, immunotherapy, lung neoplasms, small cell lung carcinoma, therapeutics, chemotherapy		ESMO Open20260
Evaluation of Biomarkers for Sacituzumab Govitecan in Metastatic Non-Small Cell Lung Cancer: Insights From the EVOKE-01 Study.
PMID 42447505 — cells, lung, docetaxel, antigens, surface, neoplasms, carcinoma, non-small-cell lung, biomarkers, lung neoplasms, small cell lung carcinoma, therapeutics, mutation, prognosis		Cancer Res Commun20261
Challenges for first-line therapy in elderly patients with metastatic non-small cell lung cancer.
PMID 42291373 — cells, lung, neoplasms, carcinoma, non-small-cell lung, aged, lung neoplasms, small cell lung carcinoma, therapeutics		Transl Lung Cancer Res20260
Brief Report: Real-World Comparative Effectiveness of First-Line Immune Checkpoint Inhibitor Monotherapy Versus Chemo-Immunotherapy in Metastatic NSCLC With PD-L1 More Than or Equal to 50%: A Meta-Analysis.
PMID 42293287 — progression-free survival, carcinoma, non-small-cell lung, immunotherapy, immune checkpoint inhibitors		JTO Clin Res Rep20260

Clinical Studies 53

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 3 Study Chair: 2 Study Director: 2

By phase:

Phase 3 24
Phase 2 14
N/A 12
Phase 2/Phase 3 2
Phase 1 1

By status:

Completed 28
Recruiting 10
Active not recruiting 8
Terminated 3
Unknown 3
Not yet recruiting 1

By type:

Interventional 42
Observational 11

By Monocentric/Multicentric:

monocentric 7
multicentric2to4 0
multicentric5to9 2
multicentricup10 44

Main Topics

Cohort/Consortium Investigators 3

Ongoing Clinical Trials

13 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
A Study to Test How Well ZL 1310 may Work Compared to Therapies Selected by the Investigator in Treating Patients with Relapsed Small Cell Lung Cancer
2025-522818-23-00 — cells, lung, pharmaceutical preparations, neoplasms, lung neoplasms, small cell lung carcinoma, work, therapeutics		Phase 3Not yet recruiting2026
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non Squamous Non Small Cell Lung Cancer (NSCLC)
2023-505749-14-00 — cells, lung, docetaxel, neoplasms, carcinoma, non-small-cell lung, drug-related side effects and adverse reactions, lung neoplasms, small cell lung carcinoma		Phase 3Recruiting2022
A Study of Dato DXd in Combination With Durvalumab and Carboplatin for First line Treatment of Advanced NSCLC Without Actionable Genomic Alterations
2023-505993-14-00 — cells, lung, neoplasms, carcinoma, non-small-cell lung, drug therapy, biomarkers, lung neoplasms, small cell lung carcinoma, therapeutics, carboplatin, chemotherapy		Phase 3Active not recruiting2023
A phase 3 trial comparing a therapeutic cancer vaccine OSE2101 to chemotherapy docetaxel in patients with metastatic Non Small Cell Lung Cancer (NSCLC) after immunotherapy failure
2023-509340-10-00 — cells, lung, safety, vaccines, docetaxel, neoplasms, phenotype, carcinoma, non-small-cell lung, drug therapy, immunotherapy, immune checkpoint inhibitors, lung neoplasms, small cell lung carcinoma, hla-a2 antigen, therapeutics, cancer vaccines, chemotherapy		Phase 3Recruiting2024
A study to learn more about how well sevabertinib works and how safe it is compared with standard treatment in participants who have advanced non small cell lung cancer (NSCLC) with mutations of the human epidermal growth factor receptor 2 (HER2)
2024-511319-91-00 — cells, epidermal growth factor, lung, growth, safety, neoplasms, carcinoma, non-small-cell lung, lung neoplasms, receptors, growth factor, small cell lung carcinoma, therapeutics, mutation		Phase 3Recruiting2024

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS